Thus, there was an agreement among Workshop delegates that there is no current evidence to suggest that there should be a difference in treating or monitoring patients with pituitary tumour remnant after primary surgery who are receiving GH replacement or not. This evidence concerns the gene GH1 and pituitary tumor.